Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres
1996

Prognostic Factors in Small-Cell Lung Cancer

Sample size: 770 publication Evidence: high

Author Information

Author(s): LGM J0rgensen, K 0sterlind, J Genolla, SA Gomm, JR Hernatndez, PWM Johnson, J Lober, TAW Splinter, M Szturmowicz

Hypothesis

The study investigates the influence of serum neuron-specific enolase (S-NSE) on survival duration in small-cell lung cancer (SCLC) alongside other prognostic factors.

Conclusion

S-NSE is identified as the most powerful prognostic factor for survival in small-cell lung cancer, followed by performance status and disease stage.

Supporting Evidence

  • S-NSE was increased in 81% of patients, indicating its potential as a prognostic marker.
  • Multivariable analysis showed S-NSE, performance status, and disease stage as significant prognostic factors.
  • The study established a prognostic index that segregated patients into four groups with different survival outcomes.

Takeaway

Doctors can use a blood test for a substance called S-NSE to help predict how long someone with small-cell lung cancer might live.

Methodology

A retrospective multicentre study analyzing data from 770 patients using Cox's proportional hazard model.

Limitations

The study may be limited by variations in treatment regimens and assessment of performance status across different centers.

Participant Demographics

The median age of participants varied from 58 to 69 years, with a predominance of male patients (69-95%).

Statistical Information

P-Value

p<0.0001

Confidence Interval

95% confidence intervals for median survival were provided for different prognostic groups.

Statistical Significance

p<0.0001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication